Brief: Arrowhead Subsidiary Visirna Sells Rights To Hypertriglyceridemia Candidate Plozasiran In Greater China To Sanofi
01/08/2025 11:42
Aug 1 (Reuters) - Arrowhead Pharmaceuticals Inc ARWR.O: ARROWHEAD SUBSIDIARY VISIRNA SELLS RIGHTS TO HYPERTRIGLYCERIDEMIA CANDIDATE PLOZASIRAN IN GREATER CHINA TO SANOFI ARROWHEAD PHARMACEUTICALS INC - SANOFI TO PAY $130 MILLION UPFRONT, $265 MILLION IN MILESTONES ARROWHEAD PHARMACEUTICALS INC - SANOFI RECEIVES EXCLUSIVE LICENSE FOR PLOZASIRAN IN CHINA Source text: ID:nBw8kLH3Ca Further company coverage: ARWR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arrowhead Pharmaceuticals
See all newsBrief: Uk's MHRA Authorises Redemplo For Adults With Familial Chylomicronaemia Syndrome
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Brief: Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers